Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,092 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and impact of other malignancies after immunochemotherapy by fludarabine, cyclophosphamide, and rituximab as frontline treatment for chronic lymphocytic leukemia: A single-center retrospective study.
Stocker N, Alsuliman T, Corre E, Ricard L, Kaoui F, Coppo P, Brissot E, Dulery R, Banet A, Van de Wyngaert Z, Legrand O, Bonnin A, Mohty M, Malard F, Marjanovic Z. Stocker N, et al. Among authors: mohty m. Clin Hematol Int. 2025 Jan 3;7(1):1-9. doi: 10.46989/001c.127828. eCollection 2025. Clin Hematol Int. 2025. PMID: 39764201 Free PMC article.
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse.
Touzeau C, Leleu X, Tiab M, Macro M, Perrot A, Gay J, Chateleix C, Moreau S, Karlin L, Jacquet C, Manier S, Hulin C, Decaux O, Richez V, Chalopin T, Mohty M, Orsini-Piocelle F, Caillot D, Sonntag C, Vignon M, Bobin A, Avet-Loiseau H, Jobert A, Planche L, Corre J, Moreau P. Touzeau C, et al. Among authors: mohty m. Br J Haematol. 2025 Jan 5. doi: 10.1111/bjh.19978. Online ahead of print. Br J Haematol. 2025. PMID: 39757748
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Duque-Afonso J, Finke J, Ngoya M, Galimard JE, Schetelig J, Eder M, Rösler W, Bug G, Neubauer A, Edinger M, Wulf GG, Jindra P, Einsele H, Stelljes M, Selleslag D, Wagner-Drouet EM, Bunjes D, Spyridonidis A, Brissot E, Nagler A, Ciceri F, Mohty M. Duque-Afonso J, et al. Among authors: mohty m. Bone Marrow Transplant. 2024 Dec 19. doi: 10.1038/s41409-024-02499-6. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39702670
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.
Malard F, Bobin A, Labopin M, Karlin L, Frenzel L, Roussel M, Vignon M, Godet S, Chalopin T, Moyer P, Chalayer E, Orsini Piocelle F, Mariette C, Croizier C, Sohn C, Dib M, Le Calloch R, Ali-Ammar N, Loirat M, Benbrahim O, Payssot A, Trebouet A, Perrot A, Leleu X, Mohty M. Malard F, et al. Among authors: mohty m. Blood Cancer J. 2024 Dec 18;14(1):219. doi: 10.1038/s41408-024-01200-w. Blood Cancer J. 2024. PMID: 39695076 Free PMC article. No abstract available.
Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working Party.
Brijs J, Peczynski C, Boreland W, Cuoghi A, Maertens J, Mohty M, Kröger N, Nakov P, Broers AEC, Eder M, Herrera Arroyo C, Kaufmann M, Ram R, Schaap NPM, Graham C, Mussetti A, Penack O, Moiseev I, Peric Z, Schoemans H. Brijs J, et al. Among authors: mohty m. Bone Marrow Transplant. 2024 Dec 13. doi: 10.1038/s41409-024-02497-8. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39668190 No abstract available.
Minimal residual disease in multiple myeloma.
Moukalled N, Malard F, Bazarbachi A, Mohty M. Moukalled N, et al. Among authors: mohty m. Presse Med. 2024 Dec 9;54(1):104261. doi: 10.1016/j.lpm.2024.104261. Online ahead of print. Presse Med. 2024. PMID: 39662763
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program.
Perrot A, Hulin C, Boumendil A, Manjra H, Leveque A, Croizier C, Dony A, Mohty M, Roussel M, Manier S, Orsini-Piocelle F, Bauschert L, Bobin A, Frenzel L, Vincent L, Breal C, Eveillard JR, Gerome T, Tiab M, Chalayer E, Belkhir R, Mariette C, Moyer P, Chalopin T, Cherel B, Montes L, Coste A, Tabrizi R, Karlin L, Robu D, Huguet A, Harel S, Moreau P. Perrot A, et al. Among authors: mohty m. Haematologica. 2024 Nov 21. doi: 10.3324/haematol.2024.286118. Online ahead of print. Haematologica. 2024. PMID: 39568438 Free article.
The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13).
Schmälter AK, Labopin M, Versluis J, Gallego Hernanz MP, Eder M, von dem Borne P, Socié G, Chevallier P, Forcade E, Neubauer A, Baron F, Bazarbachi A, Bug G, Nagler A, Schmid C, Esteve J, Mohty M, Ciceri F. Schmälter AK, et al. Among authors: mohty m. Am J Hematol. 2025 Jan;100(1):85-92. doi: 10.1002/ajh.27496. Epub 2024 Nov 18. Am J Hematol. 2025. PMID: 39558209 Free PMC article.
1,092 results